CEO: Gerry Proehl

Advent Contact: Kaasim Mahmood

Specialty pharmaceutical company focused on gastrointestinal diseases

Santarus was focused on proprietary gastro-intestinal products for patients treated by physician specialists.

Advent invested in 2001. The company listed on NASDAQ in 2004 (NASDAQ:SNTS), and was acquired in 2013 by Salix Pharmaceuticals for $2.6B.


Salix Pharmaceuticals Completes Acquisition of Santarus